![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
755kB |
![[thumbnail of Supporting Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supporting Information)
8MB |
| Item Type: | Article |
|---|---|
| Title: | Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk |
| Creators Name: | Schneider, L.S., Freiesleben, S.D., van Breukelen, G., Wang, X., Brosseron, F., Heneka, M.T., Teipel, S., Kleineidam, L., Stark, M., Roy-Kluth, N., Wagner, M., Spottke, A., Schmid, M., Roeske, S., Laske, C., Munk, M.H., Perneczky, R., Rauchmann, B.S., Buerger, K., Janowitz, D., Düzel, E., Glanz, W., Jessen, F., Rostamzadeh, A., Wiltfang, J., Bartels, C., Kilimann, I., Schneider, A., Fliessbach, K., Priller, J., Spruth, E.J., Hellmann-Regen, J. and Peters, O. |
| Abstract: | INTRODUCTION: The beneficial effects of amyloid beta 1-38, or Aβ(1-38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1-38) and AD progression. METHODS: Cognitive function and diagnostic change were assessed annually for 3 years in 177 Aβ-positive participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia from the German Center for Neurodegenerative Diseases (DZNE) longitudinal cognitive impairment and dementia study (DELCODE) cohort using the Mini-Mental State Examination (MMSE), Preclinical Alzheimer's Cognitive Composite (PACC), Clinical Dementia Rating (CDR), and National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Mixed linear and Cox regression analyses were conducted. CSF was collected at baseline. RESULTS: Higher Aβ(1-38) levels were associated with slower PACC (p = 0.001) and slower CDR Sum of Boxes (CDR-SB) (p = 0.002) but not MMSE decline. Including Aβ(1-40) beyond Aβ(1-38) in the model confirmed an association of Aβ(1-38) with slower PACC decline (p = 0.005), but not with CDR-SB or MMSE decline. In addition, higher Aβ(1-38) baseline levels were associated with a reduced dementia conversion risk. DISCUSSION: Further research is needed to understand the role of Aβ(1-38) in AD and its potential for future therapeutic strategies. |
| Keywords: | AD Conversion Risk, Alzheimer’s Disease, Aβ(1-38), Cerebrospinal Fluid, Cognitive Decline, Neuro-Toxicity, Protective Factor, Shorter Aβ Peptides |
| Source: | Alzheimer's & Dementia |
| ISSN: | 1552-5260 |
| Publisher: | Wiley |
| Page Range: | e14545 |
| Date: | 27 January 2025 |
| Official Publication: | https://doi.org/10.1002/alz.14545 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
